AI Analyst Summary
Stryker's 44.1% YoY EPS growth — driven by surgical procedure volume recovery, MedSurg momentum, and margin expansion — is the standout bull thesis, with the forward P/E compressing to 19.8x suggesting the market has yet to fully price in the earnings inflection. A PEG of 1.60 and near-universal Buy consensus among 25 analysts reinforce the constructive setup, with a consensus price target implying ~15% upside from current levels. The primary risk is valuation sensitivity: at a trailing 35.2x P/E, any guidance miss or macro-driven elective procedure slowdown could compress multiples meaningfully.
Fundamentals
Pe
Trailing P/E 35.2x / Forward P/E 19.8x · 3.0/5
Trailing P/E of 35.2x is above the broader healthcare/medical devices sector median, but the forward P/E of 19.8x reflects meaningful near-term earnings expansion. Valuation is elevated on a trailing basis but more reasonable looking ahead, warranting a neutral score.
Peg
PEG 1.60 · 4.0/5
A PEG of 1.60 is constructive for a large-cap medical device leader with durable end-market demand. Below the 2.0 threshold that would signal stretched growth-adjusted valuation, indicating above-average value relative to growth.
Analyst Rating
Buy consensus (1.7) · 4.0/5
Consensus of 1.7 on the inverted scale reflects a strong Buy skew with 22 Buy ratings, 6 Holds, and 0 Sells across 25 analysts. Broad analyst coverage with minimal bearish dissent supports a score of 4.
Earnings Trend
EPS growth +44.1% YoY | Revenue growth +9.4% YoY · 5.0/5
44.1% YoY earnings growth is well above the 25% threshold for a top score and is underpinned by solid 9.4% revenue growth, indicating strong operational leverage. Earnings trajectory is sharply positive and materially outpacing sector peers.
Price Target Beat
3 of 4 quarters beat (last 4 reported) · 3.0/5
Only 4 quarters of data are available, so the score is capped at 3 per insufficient history rules. 3-of-4 beats is a positive signal but cannot be extrapolated to a full 8-quarter track record.
Management
Consistent execution with strong analyst confidence · 4.0/5
A 75% EPS beat rate over the available period, combined with strong Buy-skewed analyst sentiment and robust earnings leverage, points to disciplined capital allocation and reliable operational execution. Score reflects constructive but not perfect history given limited beat-rate data.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Start free for 3 days →
No credit card. Then $9/month. Cancel anytime.
How Compass scores stocks
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.